The filing is a routine amendment with no change in stake or intent. Monitor for any future conversion to a Schedule 13D, which would signal activist intent, or for any exercise of the warrant that would increase the stake above 9.99%.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 11 $2.75entry
- T+1 · 10d ago +3.27%α +3.63% · $2.84
- T+5 · 4d ago −12.36%α −8.47% · $2.41
- T+7 · todayOpen
- T+20 · in 18d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Intracoastal Capital LLC and its principals filed an amended Schedule 13G disclosing a 9.99% passive stake in Sunshine Biopharma, consisting of 430,336 shares issuable upon exercise of a warrant. The stake is unchanged from the prior filing, and the filing certifies no intent to influence control.
Key Financial Metrics
Key Facts
- Intracoastal Capital LLC and its principals Mitchell P. Kopin and Daniel B. Asher filed an amended Schedule 13G.
- The filing reports beneficial ownership of 430,336 shares of common stock issuable upon exercise of a warrant.
- The stake represents approximately 9.99% of the outstanding common stock based on 3,877,337 shares outstanding plus the 430,336 warrant shares.
- The warrant contains a blocker provision preventing exercise above 9.99% beneficial ownership.
- Without the blocker, the reporting persons would be deemed to beneficially own 4,316,434 shares.
- The filing certifies the securities were not acquired with the purpose of changing or influencing control of the issuer.
- This is an amendment to a prior Schedule 13G; the stake percentage is unchanged from the prior filing.
Financial Impact
No change in stake; passive filing with no financial impact.
Risk Factors
- The blocker provision limits the stake to 9.99%, but the warrant could be exercised if the blocker is removed or modified.
- The company has a very small market cap ($2M), making it sensitive to large holder actions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0001213900-26-118164 |
| Document: 0001213900-26-118164-index.html | 0001213900-26-118164 |
| Document: 0001213900-26-118164.txt | 0001213900-26-118164 |
Track record
15 reports on SBFM
7 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +69.19% at T+20 after the Oct 8, 2026 report. 9 of 9 went positive at some point.
Filters
- Nov 18, 20263d ago S-1 Bearish 6/10 Entry $2.35 Now $2.23 +5.11% settles Nov 27
- Nov 13, 20268d ago DEFA14A Bearish 5/10 Entry $2.60 Now $2.23 +14.23% settles Nov 23
- Nov 12, 20269d ago DEF 14A Bearish 5/10 Entry $2.70 to $2.23 Now $2.23 +17.41% ▲ +17.41% +8.85% vs SPY
- Nov 10, 202611d ago SC 13G/A Neutral 2/10 Viewing Entry $2.75 to $2.41 Now $2.23 −18.91% ▼ −12.36% −8.47% vs SPY
- Oct 14, 20265w ago SC 13G Neutral 3/10 Entry $0.2430 to $0.2154 Now $2.23 +817.70% ▼ −11.36% −11.81% vs SPY
- Oct 13, 20265w ago SC 13G Neutral 4/10 Entry $0.2430 to $0.2154 Now $2.23 +817.70% ▼ −11.36% −11.81% vs SPY
- Oct 9, 20266w ago 8-K Bearish 6/10 Entry $0.3020 to $0.2418 Now $2.23 −638.41% ▲ +19.93% +18.44% vs SPY
- Oct 9, 20266w ago 424B4 Bearish 7/10 Entry $0.3020 to $0.2418 Now $2.23 −638.41% ▲ +19.93% +18.44% vs SPY
- Oct 8, 20266w ago EFFECT Bearish 6/10 Entry $8.60 to $4.60 Now $2.23 +74.07% ▲ +46.51% +46.24% vs SPY
- Oct 5, 20266w ago SC 13G/A Bearish 5/10 Entry $0.3979 to $0.2363 Now $2.23 −460.44% ▲ +40.61% +40.47% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers